Cowen and Company’s Cytokinetics CYTK Stock Holding History

Cowen and Company’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-56,828	Closed	-$4.4M	–	689
2023 Q4	$4.74M	Buy	+56,828	New	+$2.06M	0.31%	54

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Cowen and Company's CYTK Position: Q1 2024 in Review

Cowen and Company sold out of Cytokinetics (CYTK) in Q1 2024, closing a stake of 56,828 shares — an estimated $4.4M sold.

Cowen and Company first reported a position in CYTK in Q4 2023 and held it in 1 quarter. The position peaked at $4.74M in Q4 2023. 390 funds tracked by Wall St. Rank hold CYTK as of Q1 2024.

Cowen and Company reported no remaining Cytokinetics position as of Q1 2024 after selling out during the quarter.
Cowen and Company sold 56,828 Cytokinetics shares in Q1 2024, an estimated $4.4M.
Cowen and Company first reported a position in Cytokinetics in Q4 2023 and held it in 1 quarter.
Cowen and Company's Cytokinetics position peaked at $4.74M in Q4 2023.
390 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.